Companion Bio is a therapeutics company focused on age-related diseases. We leverage first-in-class therapeutics with diagnostics assays that predict disease before it is established and when its course can be more readily altered through strategic interventions.

Acquired a small molecule from Pfizer and took it in phase III in MBC. Responsible for the organization's commercial (redesigned the website 3x) and business development activities. Also responsible for initiating and managing clinical studies (phase I and II) with major academic centers.

I started as a consultant for Natera in 2016. In 2017, I became a full-time employee for Natera with the launch of Signatera. Signatera is the first diagnostic individualized to a cancer patients unique cancer signature. Signatera was partnered with greater than fifteen pharma companies in the first six months of launch (an industry first for uptake of a new product).

Cynvenio's LiquidBiopsy system is a distributable, automated, comprehensive workflow for isolation, enrichment, and NGS analysis of germline white blood cells, circulating tumor cells (CTCs), and cell free DNA (cfDNA) from a single blood draw and without the need for whole genome amplification (WGA).

Asuragen is a global diagnostic products company delivering solutions that build knowledge and understanding of complex clinical questions. With innovative approaches to kit development and a broad range of molecular chemistries, Asuragen produces assays that ensure reproducible results. From discovery and development to regulatory support to global commercialization, we also provide a tailored approach that efficiently delivers custom and companion diagnostic products for our partners. • Developed and implemented new strategies and product offerings by leading task forces that operated from pre-phase 0 through revenue generation• Filtered and prioritized business development opportunities through internal and external groups with defined processes and decision trees• Accountable for the business development team leading strategic partnerships, alliances, licensing and royalty agreements, OEM agreements, commercialization/distribution agreements, and transactional services• Facilitated cross-functional teams through high value negotiations which significantly increased the company’s valuation: Several CDx agreements with full IP ownership of diagnostic intellectual property, Illumina CDx collaboration agreement (IVD rights), agreement with undisclosed ddPCR company, and royalty agreements with Asuragen’s proprietary Armored RNA technology• Performed financial modeling and diligence for strategic business development opportunities ie NPV, IRR, cost and deal structure• Accountable for developing budgets, managing personnel, and the P&L for the business development, alliance management, and scientific affairs teams (10 direct reports in 2015)• Created and managed the scientific affairs team tasked with engaging and nurturing a KOL network and scientific advisory board• Responsible for the commercial operations and forecasting of the custom and companion diagnostics group

• Accountable for the business development team responsible for strategic partnerships with pharmaceutical companies, contract research organizations, and clinical reference laboratories• Negotiated deals which involved milestones and multi-directional IP clauses• Initiated an agreement process which utilized Miller Heiman principles for gaining consensus internally and externally• Managed an independent cost center which exceeded gross margin goal of 75% in 2013• Developed and implemented a new strategies and products offering from pre-phase 0 to revenue generation• Performed financial modeling and diligence for life science based business development opportunities ie NPV, IRR, cost and deal structure• Identified and developed new market opportunities for the qNPA chemistry o FGFR, Immuno-Oncology, COO/DLBCL and HER family panels• Managed the launch of a new diagnostic platform (EDGE) and into pharmaceutical markets and large reference laboratories• Executed partnership agreements with leading clinical and research laboratories (Labcorp and Quintiles)• Managed the Business Development and Scientific Affairs Directors (3 direct reports)

• Business Development and Alliance Manager on multiple joint CDx project teams which drove over $25MM in annual revenue• Led cross-functional teams through agreement negotiations for high value partnerships; including complex intellectual property discussions• Key member of a CDx commercialization launch team that included: advisory boards, early adopters and compassionate use programs• On-boarded team members, lead cross-functional training discussions on business development and contract management

• Key member of the corporate development team; raised $11 million Series A investment from Summit Partners • Crafted Apocell’s strategic vision of becoming the leading rare cell (CTC and CEC) company• Designed and implemented Apocell’s marketing strategy (website, brochures, e-marketing, booth and products)• Managed both the Global Sales and Marketing teams

• Managed co-development partnerships with pharmaceutical and diagnostic companies for Veridex’s RUI and IVD products• Member of the Johnson & Johnson High Potential Group (Leadership Development Program) • JNJ Life Science Specialist of the year and Ambassador Club award winner 2006

• Rank #1 (of 32) in the country for FY 2003 demand creation activities with physicians• Ranked #2 in the sales of new molecular products in 2004 • 2003 Abbott Laboratories Presidents Club award winner